ConductScience.org, home

Paper40144648

Antioxidants for the management of oral leukoplakia: A systematic review of randomized controlled trials.

Gopinath D and 3 others. J Oral Biol Craniofac Res, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Antioxidants for the management of oral leukoplakia: A systematic review of randomized controlled trials. Papers, record 40144648. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40144648

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antioxidants for the management of oral leukoplakia: A systematic review of randomized controlled trials.
PubMed
Journal
J Oral Biol Craniofac Res
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-03-28
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gopinath DDivya
2Waki SISara Ibrahim
3Cheah KFKwok Fu
4Panda SSwagatika

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123970935Multiple molecular and cellular mechanisms of action of lycopene in cancer inhibition.Evid Based Complement Alternat Med2013https://conductscience.org/library/papers/23970935PubMed
230443884Malignant transformation of oral leukoplakia treated with carbon dioxide laser: a meta-analysis.Lasers Med Sci2019https://conductscience.org/library/papers/30443884PubMed
336656190A comparative investigation of the activity of superoxide dismutase in patients with leukoplakia and healthy controls.Indian J Dent Res2022https://conductscience.org/library/papers/36656190PubMed
429952268A Review on Free Radicals and Antioxidants.Infect Disord Drug Targets2020https://conductscience.org/library/papers/29952268PubMed
521299897Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.Mol Cancer2011https://conductscience.org/library/papers/21299897PubMed
637760056Antioxidant Use after Diagnosis of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review of Application during Radiotherapy and in Second Primary Cancer Prevention.Antioxidants (Basel)2023https://conductscience.org/library/papers/37760056PubMed
728929051Comparison of effectiveness of Calendula officinalis extract gel with lycopene gel for treatment of tobacco-induced homogeneous leukoplakia: A randomized clinical trial.Int J Pharm Investig2017https://conductscience.org/library/papers/28929051PubMed
831462531RoB 2: a revised tool for assessing risk of bias in randomised trials.BMJ2019https://conductscience.org/library/papers/31462531PubMed
938938085Surgical treatment compared with "wait and see" in patients affected by oral leukoplakia to prevent oral cancer: Preliminary data from a multicenter randomized controlled trial.Oral Dis2025https://conductscience.org/library/papers/38938085PubMed
1024932187Oxidant-antioxidant status in tissue samples of oral leukoplakia.Dent Res J (Isfahan)2014https://conductscience.org/library/papers/24932187PubMed
1138155549Antioxidant treatments in patients with oral submucous fibrosis: A systematic review.J Oral Pathol Med2024https://conductscience.org/library/papers/38155549PubMed
1231981993Oral potentially malignant disorders: A comprehensive review on clinical aspects and management.Oral Oncol2020https://conductscience.org/library/papers/31981993PubMed
1315116757Biological properties of curcumin-cellular and molecular mechanisms of action.Crit Rev Food Sci Nutr2004https://conductscience.org/library/papers/15116757PubMed
1437971722Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.JAMA Oncol2024https://conductscience.org/library/papers/37971722PubMed
1527656569Prevalence of Carcinomatous Foci in Oral Leukoplakia: A Clinicopathologic Study of 546 Indian Samples.J Clin Diagn Res2016https://conductscience.org/library/papers/27656569PubMed
1625156040Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: a randomized controlled trial.Int J Cancer2015https://conductscience.org/library/papers/25156040PubMed
1727865803Leukoplakia-A Diagnostic and Management Algorithm.J Oral Maxillofac Surg2017https://conductscience.org/library/papers/27865803PubMed
1838654673Oral leukoplakia treated with laser and scalpel: Interim trial results of recurrence and malignancy.Oral Dis2024https://conductscience.org/library/papers/38654673PubMed
1938817004Clinical aspects of oral cancer and potentially malignant disorders in South and Southeast Asia.Oral Dis2025https://conductscience.org/library/papers/38817004PubMed
2027267893A Randomized Double-Blind Placebo-Controlled Phase IIB Trial of Curcumin in Oral Leukoplakia.Cancer Prev Res (Phila)2016https://conductscience.org/library/papers/27267893PubMed

See all 48 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40144648

GET https://conductscience.org/api/papers/v1/40144648/references?page=2